Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Revenue (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Revenue for 4 consecutive years, with $107.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 17.52% to $107.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $389.1 million through Dec 2025, up 33.93% year-over-year, with the annual reading at $389.1 million for FY2025, 33.93% up from the prior year.
  • Revenue hit $107.1 million in Q4 2025 for Krystal Biotech, up from $97.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $107.1 million in Q4 2025 to a low of -$1.5 million in Q1 2021.
  • Historically, Revenue has averaged $66.3 million across 4 years, with a median of $83.8 million in 2024.
  • Biggest five-year swings in Revenue: skyrocketed 879.43% in 2024 and later increased 16.71% in 2025.
  • Year by year, Revenue stood at -$1.5 million in 2021, then skyrocketed by 2924.66% to $42.1 million in 2023, then skyrocketed by 116.2% to $91.1 million in 2024, then increased by 17.52% to $107.1 million in 2025.
  • Business Quant data shows Revenue for KRYS at $107.1 million in Q4 2025, $97.8 million in Q3 2025, and $96.0 million in Q2 2025.